文献速递乳腺外科

找到「真正」的N0队列:非小细胞肺癌近红外前哨淋巴结示踪的技术要点

Finding the "True" N0 Cohort: Technical Aspects of Near-infrared Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer.
PubMed 文献 · Ann Surg · 2020-01-01

该研究回顾性分析两项I期临床试验,评估ICG近红外引导前哨淋巴结示踪在可手术非小细胞肺癌中的技术因素。结果显示ICG剂量≥1mg、白蛋白溶解、注射后肺通气、实性结节和解剖性切除与更高的SLN识别率相关。经SLN病理阴性确定的N0患者无病生存和总生存均为100%,优于仅常规淋巴结清扫确定的N0患者。

要点

  • ICG剂量≥1mg、白蛋白溶解、注射后肺通气可提高SLN识别率。
  • 实性结节和解剖性切除在优化注射后SLN识别率更高。
  • SLN病理阴性确定的N0患者生存优于仅常规清扫确定的N0。

核心结论

  • ICG剂量≥1mg、白蛋白溶解、注射后肺通气、影像学实性结节和解剖性切除时SLN识别更可靠。
  • 经近红外SLN示踪确定的N0状态似乎与术后复发减少和生存改善相关。

研究设计与样本

  • 回顾性分析两项I期临床试验,纳入可手术切除的非小细胞肺癌患者。
  • 共66例患者接受瘤周ICG注射后近红外引导SLN示踪及淋巴结清扫。

主要发现

  • ICG剂量≥1mg相比<1mg的SLN识别率为65.2% vs 35.0%(P=0.05)。
  • 注射后肺通气相比无通气的SLN识别率为65.2% vs 35.0%(P=0.05)。
  • 白蛋白溶解的SLN识别率为68.1%,新鲜冰冻血浆为28.6%,无菌水为20.0%(P=0.01)。
  • 优化ICG注射后,实性结节相比亚实性结节的SLN识别率为77.4% vs 33.3%(P=0.04)。
  • 优化ICG注射后,解剖性切除相比楔形切除的SLN识别率为88.2% vs 52.2%(P=0.04)。

关键数值与推荐

  • SLN病理阴性确定N0的患者(n=25)无病生存和总生存均为100%。
  • 仅常规淋巴结清扫确定N0的患者(n=22)无病生存为73.6%(P=0.02),总生存为63.6%(P=0.01)。

临床怎么用

  • 在非小细胞肺癌近红外SLN示踪中,建议ICG剂量≥1mg并使用白蛋白溶解。
  • 注射后应进行肺通气,对实性结节和解剖性切除患者SLN识别更可靠。
  • SLN示踪有助于发现常规清扫遗漏的隐匿淋巴结病变,可能改善分期。

局限性

  • 回顾性分析,样本量较小(共66例)。
  • 研究基于两项I期临床试验数据,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine technical-, patient-, tumor-, and treatment-related factors associated with NIR guided SLN identification. BACKGROUND: Missed nodal disease correlates with recurrence in early stage NSCLC. NIR-guided SLN mapping may improve staging and outcomes through identification of occult nodal disease. METHODS: Retrospective analysis of 2 phase I clinical trials investigating NIR-guided SLN mapping utilizing ICG in patients with surgically resectable NSCLC. RESULTS: In total, 66 patients underwent NIR-guided SLN mapping and lymphadenectomy after peritumoral ICG injection. There was significantly increased likelihood of SLN identification with injection dose ≥1 mg compared to <1 mg (65.2% vs 35.0%, P = 0.05), lung ventilation after injection (65.2% vs 35.0%, P = 0.05), and albumin dissolvent (68.1%) compared to fresh frozen plasma (28.6%) and sterile water (20.0%) (P = 0.01). In patients receiving the optimized ICG injection, there was significantly increased likelihood of SLN identification with radiologically solid nodules compared to sub-solid nodules (77.4% vs 33.3%, P = 0.04) and anatomic resection compared to wedge resection (88.2% vs 52.2%, P = 0.04). Disease-free and overall survival are 100% in those with a histologically negative SLN identified (n = 25) compared to 73.6% (P = 0.02) and 63.6% (P = 0.01) in patients with node negative NSCLC established via routine lymphadenectomy alone (n = 22). CONCLUSIONS: SLN(s) are more reliably identified with ICG dose ≥1 mg, albumin dissolvent, post-injection lung ventilation, radiologically solid nodules, and anatomic resections. To date, N0 status when established via NIR SLN mapping seems to be associated with decreased recurrence and improved survival after surgery for NSCLC.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Phillips WW, Weiss KD, Digesu CS, et al. Finding the "True" N0 Cohort: Technical Aspects of Near-infrared Sentinel Lymph Node Mapping in Non-small Cell Lung Cancer. Ann Surg. 2020. PMID: 32657925. doi:10.1097/SLA.0000000000004176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。